Clinical trial NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Official title: A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Relapsed/Refractory Multiple Myeloma
Lead sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-07-19
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This Study consists of Stage 1 and Stage 2.

Stage 1 ：Single group. Subjects will receive SG301 Injection in combination with pomalidomide and dexamethasone.

Stage 2：Parallel. Subjects will be randomized to receive SG301 Injection in combination with pomalidomide and dexamethasone or placebo in combination with pomalidomide and dexamethasone.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Detailed description: This is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study to compare SG301 injection in combination with pomalidomide and dexamethasone versus placebo in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 prior treatment regimen with both lenalidomide and a proteasome inhibitor and have demonstrated disease progression.

This study consists of two stages. Stage 1 is the dose exploration stage to confirm the recommended stage 2 dose of SG301 injection in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Stage 2 is the randomized controlled stage of SG301 injection in combination with pomalidomide and dexamethasone versus placebo in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Eligibility criteria: Inclusion Criteria:

1. Understand and voluntarily sign the informed consent form (ICF).
2. Males and females aged 18-75 years (inclusive)
3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2
4. Expected survival time of ≥3 months.
5. Subjects had a documented diagnosis of multiple myeloma with evidence of measurable disease.
6. Subjects had received at least 1 prior lines of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.
7. Subjects must have documented evidence of PD on or after the last regimen.
8. Adequate function of vital organs
9. Women of childbearing potential (WOCBP) must agree to follow instructions for methods of contraception for 4 weeks before the start of study treatment, for the duration of study treatment, and for 6 months after cessation of SG301 or 4 weeks after cessation of pomalidomide, whichever is longer. WOCBP must have 2 negative serum or urine pregnancy tests, one 10-14 days prior to start of study treatment and one 24 hours prior to the start of study treatment.

Exclusion Criteria:

1. Primary refractory multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.
2. Bone independent extramedullary disease at screening.
3. Subjects who are primary refractory to a prior CD38 monoclonal antibody therapy.
4. Previous exposure to pomalidomide.
5. Subject has received chemotherapy or small molecule antitumor therapy within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;
6. Subject has received tumor biotherapy within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;
7. Subject has received investigational agents within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter (but not less than 14 days), before the first dose of study treatment;
8. Active hepatitis B, or C.
9. Known HIV infection.
10. Known active tuberculosis or positive treponema pallidum antibodies.
11. Subjects with clinical significant organ dysfunction that does not meet the study needs.
12. Previous allogenic stem cell transplant or autologous stem cell transplantation (ASCT) before the first dose of study treatment.
13. Known allergy to any component of the investigational medicinal product.
14. Any concurrent medical or psychiatric condition or disease (eg, active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results or that, in the opinion of the investigator, would constitute a hazard for participating in this study.

Primary outcomes:
measure: Adverse events （stage 1）
timeFrame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
measure: Recommended stage 2 dose of SG301 (Stage 1)
timeFrame: Up to approximately 6 months.
measure: Progression Free Survival (Stage 2)
timeFrame: From baseline through the end of study. Assessed every 4 weeks after randomization until C19D1, and every 8 weeks thereafter until disease progression (IMWG criteria) or death whichever occurs first, assessed up to approximately 4 years.
Secondary outcomes:
measure: Pharmacokinetics (PK): AUC
timeFrame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
measure: Pharmacokinetics (PK): Cmax
timeFrame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
measure: Pharmacokinetics (PK):limination half-life (T1/2)
timeFrame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
measure: Immunogenicity endpoints
timeFrame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
measure: Overall Response Rate
timeFrame: From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.
measure: Percentage of Participants With Very Good Partial Response (VGPR) or Better (≥VGPR Rate)
timeFrame: From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.
measure: Duration of Response
timeFrame: From baseline through the end of study. It is measured from the time that the criteria for objective response are first met until the date of a progression event, assessed up to approximately 4 years.
measure: Overall Survival
timeFrame: From baseline through the end of study, assessed up to approximately 4 years.
measure: Percentage of Participants With Minimal Residual Disease (MRD)
timeFrame: From baseline through the end of study. It is measured from the time that the criteria for CR are first met until the date of a progression event, assessed up to approximately 4 years.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Chaoyang Hospital of Capital Medical University
state: Beijing
city: Guangzhou
country: China
facility: Guangzhou First People's Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
city: Luoyang
country: China
facility: First Affiliated Hospital of Henan University of Science and Technology
state: Henan
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Wuhan
country: China
facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
city: Suzhou
country: China
facility: The First Affiliated Hospital Of Soochow University
state: Jiangsu
city: Taiyuan
country: China
facility: Shanxi Provincial Hospital
state: Shanxi
city: Xi'an
country: China
facility: The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
state: Shanxi
city: Tianjin
country: China
facility: Tianjin Cancer University Airport Hospital
state: Tianjin
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
state: Tianjin
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School Of Medicine
state: Zhejiang
Study officials:
References: